Bullfrog AI Holdings, Inc. (BFRG)
| Market Cap | 12.55M -27.9% |
| Revenue (ttm) | 116,670 |
| Net Income | -6.07M |
| EPS | -0.54 |
| Shares Out | 18.53M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 141,679 |
| Open | 0.6600 |
| Previous Close | 0.6691 |
| Day's Range | 0.6600 - 0.6980 |
| 52-Week Range | 0.4251 - 2.0400 |
| Beta | -2.89 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 14, 2026 |
About BFRG
Bullfrog AI Holdings, Inc. operates as a digital biopharmaceutical company that focuses on artificial intelligence and machine learning (AI/ML) driven analysis of data sets in medicine and healthcare in the United States. The company offers bfLEAP, an analytical AI/ML platform to analyze preclinical and clinical data for biotechnology and pharmaceutical companies, and other organizations. It also develops BF-222, a novel formulation of mebendazole , which is in the first phase for the treatment of Glioblastoma; BF-223, a novel prodrug of mebend... [Read more]
Financial Performance
Financial StatementsNews
BullFrog AI Announces New Commercial Leadership Team to Execute Growth Strategy for its Integrated Pharma AI Platform
GAITHERSBURG, Md., June 02, 2026 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology company using artificial intelligence (“AI”) and ma...
BullFrog AI Regains Compliance with Nasdaq Shareholders' Equity Requirement
GAITHERSBURG, Md., April 22, 2026 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology company using artificial intelligence (“AI”) and m...
BullFrog AI Announces Participation at AACR Annual Meeting
BullFrog AI team will be available to discuss its end-to-end drug discovery and development workflow at booth 2957 BullFrog AI team will be available to discuss its end-to-end drug discovery and devel...
BullFrog AI Provides Business Update: Strengthened Balance Sheet Supports Continued Execution as Company Aims to Ramp Commercial Activity with Global Pharmaceutical and Biotechnology Partners
GAITHERSBURG, Md., April 13, 2026 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (Nasdaq: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology company using artificial intelligence and machine ...
Bullfrog AI stock offers a rare opportunity for investors to take profit
Bullfrog AI Inc more than doubled on Mar. 30 after announcing a landmark commercial agreement with a “top 5” pharma leader to identify novel therapeutic targets for Major Depressive Disorder. In its p...
BullFrog AI Announces Commercial Agreement with Top 5 Global Pharmaceutical Company to Identify and Prioritize Therapeutic Target in Major Depressive Disorder
GAITHERSBURG, Md., March 30, 2026 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) (“BullFrog AI” or the “Company”), a technology company using artificial intelligence (“AI”) and m...
BullFrog AI Unveils bfARENAS™ Scenario-based Decision Engine
Completes end-to-end AI intelligence workflow product with an advanced AI decision tool that clearly defines drug target discovery and clinical trial strategies to build diversified, risk-balanced R&D...
BullFrog to Host Webinar on New Precision AI Capability
March 27 webinar at 11 a.m. ET highlights launch of BullFrog AI's new scenario-based decision engine for pharmaceutical portfolio strategy and clinical trial design March 27 webinar at 11 a.m. ET high...
BullFrog AI to Unveil New Precision AI Capability
GAITHERSBURG, Md., Feb. 04, 2026 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology company using artificial intelligence (“AI”) and ma...
BullFrog AI-Driven Precision Oncology Analytics Identifies 3x Increase in Overall Survivability in Patient Subgroups through Key Biomarkers in Pancreatic Cancer
Company's bfLEAP® platform successfully identified treatment effect heterogeneity and possible early predictors of outcomes in pancreatic cancer in data to be presented at ASCO GI Company's bfLEAP® pl...
BullFrog AI's bfPREP™ and bfLEAP® Platforms Deliver Real-World Impact in Eleison Pharmaceuticals Collaboration
Joint oncology conference submission planned and follow-on contract discussion underway Validates BullFrog AI's enterprise-grade platform strategy, combining automation and human-in-the-loop oversight...
BullFrog AI to Present at BTIG Annual Virtual Biotechnology Conference
GAITHERSBURG, Md., July 28, 2025 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial i...
Rethinking R&D: BullFrog AI White Paper Outlines New Blueprint for Smarter Drug Development
From target discovery to trial optimization, bfLEAP™ empowers biopharma teams to predict therapeutic success with greater confidence
BullFrog AI's Dr. Juan Felipe Beltrán to Highlight Advanced AI Strategies in Bioinformatics at XTalks Webinar
GAITHERSBURG, Md., June 20, 2025 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial i...
BullFrog AI Announces Strategic Collaboration with Sygnature Discovery to Introduce BullFrog Data Networks™ to Global Biopharma Clients
GAITHERSBURG, Md., June 12, 2025 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial i...
BullFrog AI Issues Letter to Stockholders
GAITHERSBURG, Md., Dec. 27, 2024 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial i...
BullFrog AI Announces Appointment of Chief Financial Officer
GAITHERSBURG, Md., Dec. 17, 2024 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial i...
BullFrog AI's VP Artificial Intelligence to Present at Google's Cancer AI Symposium
GAITHERSBURG, Md., Oct. 22, 2024 (GLOBE NEWSWIRE) -- BullFrog AI, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligen...
WallachBeth Capital Announces Closing of Bullfrog AI Registered Direct Offering and Concurrent Private Placement for Aggregate Gross Proceeds of $3.13 Million
JERSEY CITY, N.J. , Oct. 21, 2024 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced that -- BullFrog AI Holdings, Inc. (NAS...
Bullfrog AI Announces Closing of Registered Direct Offering and Concurrent Private Placement for Aggregate Gross Proceeds of $3.13 Million
GAITHERSBURG, Md., Oct. 21, 2024 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ:BFRG; BFRGW) ("Bullfrog AI" or the "Company"), a technology-enabled drug development company using artificial in...
WallachBeth Capital Announce Pricing of Bullfrog AI's Registered Direct Offering and Concurrent Private Placement for Aggregate Gross Proceeds of $3.13 Million
JERSEY CITY, N.J. , Oct. 18, 2024 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced that BullFrog AI Holdings, Inc. (NASDAQ...
Bullfrog AI Announces Pricing of Registered Direct Offering and Concurrent Private Placement for Aggregate Gross Proceeds of $3.13 Million
GAITHERSBURG, Md., Oct. 18, 2024 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ:BFRG; BFRGW) ("Bullfrog AI" or the "Company"), a technology-enabled drug development company using artificial in...
BullFrog AI Strengthens Scientific Advisory Board with the Addition of GSK Veteran and Industry Pioneer Dr. John Baldoni
GAITHERSBURG, Md., Oct. 15, 2024 (GLOBE NEWSWIRE) -- BullFrog AI, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligen...
BullFrog AI Announces Publication of Data Supporting Potential of Liver Disease Treatment Candidate BF-114
GAITHERSBURG, Md., Oct. 09, 2024 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial i...
BullFrog AI to Participate at the H.C. Wainwright 26th Annual Global Investment Conference
GAITHERSBURG, Md., Aug. 26, 2024 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a leader in AI-driven drug discovery, announced today that the C...